GSK-256066 Completed Phase 2 Trials for Asthma Treatment
| Indications | Status | Purpose | Phase |
|---|---|---|---|
| Completed | Treatment | 2 |
| clinicaltrials.gov Identifier | Title | Drugs |
|---|---|---|
| NCT00445510 | This Study Will Examine the Effects of GSK256066 to Protect Mild Steroid-naive Asthmatics Against an Antigen Challenge | |
| NCT00549744 | Clinical Endpoint Trial Investigating Once Daily and Bronchodilator Dosing |